Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review.

Wegzyn, Colleen; Toh, Lim Kai; Notario, Gerard; Biguenet, Sophie; Unnebrink, Kristina; Park, Caroline; Makari, Doris; Norton, Michael

Wegzyn, Colleen; Toh, Lim Kai; Notario, Gerard; Biguenet, Sophie; Unnebrink, Kristina; Park, Caroline; Makari, Doris; Norton, Michael.

Afiliação

Wegzyn C; AbbVie Inc., North Chicago, IL, USA. colleen.wegzyn@abbvie.com.
Toh LK; AbbVie Pte. Ltd, Singapore, Singapore.
Notario G; AbbVie Inc., North Chicago, IL, USA.
Biguenet S; AbbVie Inc., North Chicago, IL, USA.
Unnebrink K; AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany.
Park C; AbbVie Inc., North Chicago, IL, USA.
Makari D; MedImmune, Inc., Gaithersburg, MD, USA.
Norton M; AbbVie Inc., North Chicago, IL, USA.

Infect Dis Ther ; 3(2): 133-58, 2014 Dec.

Article em En | MEDLINE | ID: mdl-25297809

Palavras-chave

Efficacy; Palivizumab; Respiratory syncytial virus; Safety; Serious lower respiratory tract infection; Systematic review

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies / Systematic_reviews Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google